H.R. 3073House116th Congress (2019-2021)In Committee

TICK Act

To provide assistance to combat the escalating burden of Lyme disease and other tick and vector-borne diseases and disorders.

Also known as Ticks: Identify, Control, and Knockout Act

Introduced June 3, 2019

AI-Generated Summary

Updated April 14, 2026 at 5:46 AM UTC

The TICK Act creates a new Office of Oversight and Coordination for Vector‑Borne Diseases within the Department of Health and Human Services to develop and oversee a national strategy for Lyme disease and other tick‑borne illnesses. It funds regional Centers of Excellence and cooperative agreements with the CDC, state, tribal and local health agencies to improve surveillance, research, diagnosis, treatment, and public education.

Key Provisions

  • Establishes an Office of Oversight and Coordination for Vector‑Borne Diseases headed by a director appointed by the HHS Secretary.
  • The Office must create an annual national strategy, assess progress, and coordinate programs across federal agencies, consulting experts and patient groups.
  • Authorizes $10 million per year (2021‑2026) for grants, contracts, or cooperative agreements to set up Regional Centers of Excellence that conduct research, surveillance, training, and outbreak response.
  • Requires regional centers to collaborate with academia, public‑health agencies, and focus on underserved areas and high‑prevalence regions.
  • Mandates cooperative agreements between the CDC and state, tribal, and local health departments, funded at $20 million per year (2021‑2026), to support education, early detection, prevention, treatment, and care planning.
  • Calls for coordination with other federal departments, the Tick‑Borne Disease Working Group, and international bodies to align efforts.

Legislative Activity

Stay on top of the latest movement without scrolling through every action

2 earlier actions
HouseCommittee Latest Action

Referred to the Subcommittee on Health.

June 4, 2019

View full timeline
HouseIntro Referral

Introduced in House

June 3, 2019

HouseIntro Referral

Referred to the House Committee on Energy and Commerce.

June 3, 2019

HouseCommittee

Referred to the Subcommittee on Health.

June 4, 2019

Floor Debate

24 members

What members said about H.R. 3073 on the floor

9 Republicans15 Democrats
Sheila Jackson Lee
Rep. Sheila Jackson LeeD-TX-18 · Jun 12, 2019

Mr. Chair, I have an amendment at the desk. Mr. Chair, just a few weeks ago, I had a roundtable discussion with health professionals and those who are suffering from diabetes. I heard the stories of…

Rosa L. DeLauro
Rep. Rosa L. DeLauroD-CT-3 · Jun 12, 2019

Mr. Chair, I rise to speak about the fiscal year 2020 appropriations bill for the Labor, Health and Human Services, Education, and Related Agencies. To start, let me recognize the ranking member, Tom…

Christopher H. Smith
Rep. Christopher H. SmithR-NJ-4 · Jun 12, 2019

Mr. Chair, I thank the gentleman very much for his amendment and for yielding. Mr. Chair, in 2009, Nurse Cathy DeCarlo was ordered at Mt. Sinai Hospital in New York, to assist in the abortion of a…

Mark DeSaulnier
Rep. Mark DeSaulnierD-CA-11 · Jun 12, 2019

Mr. Chair, I have an amendment at the desk. Mr. Chair, our economy and our Nation's workforce are at a critical juncture. The introduction of new technology and easier flow of people and information…

Peter J. Visclosky
Rep. Peter J. ViscloskyD-IN-1 · Jun 12, 2019

Mr. Chair, I would like to begin by expressing my appreciation, as I discuss the defense portion of this bill, to my ranking member, Mr. Calvert. He has made it easy to continue the collegiality,…

Show 8 more
Barbara Lee
Rep. Barbara LeeD-CA-13 · Jun 12, 2019

Mr. Chair, I thank Chairwoman Lowey for her leadership, for yielding, and for her tireless work day and night on behalf of the American people. As a member of the Labor, Health and Human Services,…

Nita M. Lowey
Rep. Nita M. LoweyD-NY-17 · Jun 12, 2019

Madam Speaker, I ask unanimous consent that all Members have 5 legislative days to revise and extend their remarks and include extraneous material on H.R. 2740. Mr. Chairman, I yield myself such time…

Steny H. Hoyer
Rep. Steny H. HoyerD-MD-5 · Jun 12, 2019

Mr. Chair, I thank the chairwoman for yielding, and I want to say I thank the chair and I thank Ms. Granger for her leadership and working with the chair, Mrs. Lowey, on getting these bills to the…

Michael K. Simpson
Rep. Michael K. SimpsonR-ID-2 · Jun 12, 2019

Mr. Chair, I thank the chairwoman for yielding time. I rise today in reluctant opposition to H.R. 2740, the four-bill fiscal 2020 appropriations package that includes the Energy and Water Development…

Dan Newhouse
Rep. Dan NewhouseR-WA-4 · Jun 12, 2019

Mr. Chair, as the designee of the gentlewoman from Texas, I move to strike the last word. Mr. Chair, I rise in support of the amendment that I introduced with my friend from Oregon (Mr. DeFazio) to…

Kay Granger
Rep. Kay GrangerR-TX-12 · Jun 12, 2019

Mr. Chair, I yield myself such time as I may consume. Mr. Chair, I rise today in opposition to H.R. 2740. The Appropriations Committee has held more than 120 hearings this year on topics ranging from…

Danny K. Davis
Rep. Danny K. DavisD-IL-7 · Jun 12, 2019

Mr. Chair, I have an amendment at the desk. Mr. Chair, I yield myself such time as I may consume. First of all, I want to thank Representative Burgess and Representative G.K. Butterfield, both of…

Ken Calvert
Rep. Ken CalvertR-CA-42 · Jun 12, 2019

Mr. Chair, I thank Ranking Member Granger and Chairwoman Lowey both for their leadership and expertise throughout this process. I also acknowledge the work of Chairman Visclosky. Mr. Chair, I am…

Show 11 more
Michael C. Burgess
Rep. Michael C. BurgessR-TX-26 · Jun 12, 2019

Mr. Chair, I claim the time in opposition to the amendment, even though I am not opposed to it. Mr. Chair, I yield myself such time as I may consume. Mr. Chair, I am glad to be cosponsoring this…

Bill Pascrell, Jr.
Rep. Bill Pascrell, Jr.D-NJ-9 · Jun 12, 2019

Mr. Chairman, I have an amendment at the desk. Mr. Chairman, I want to thank Congresswoman DeLauro and Ranking Member Cole for their support for my amendment and support for the fire services. I rise…

Marcy Kaptur
Rep. Marcy KapturD-OH-9 · Jun 12, 2019

Mr. Chairman, I thank our able Chairwoman Nita Lowey and Ranking Member Kay Granger for leading our Appropriations Committee in doing the real work of America on a bipartisan basis. Our Energy and…

Harold Rogers
Rep. Harold RogersR-KY-5 · Jun 12, 2019

Mr. Chair, I thank the distinguished Republican ranking member on the committee for this time but also, more importantly, for her wise leadership of this committee. Mr. Chair, I rise in reluctant…

Tom Cole
Rep. Tom ColeR-OK-4 · Jun 12, 2019

Mr. Chair, I thank the distinguished ranking Republican member of the Appropriations Committee, my good friend, Ms. Granger, for yielding. I want to begin, Mr. Chair, on a positive note. I want to…

Maxine Waters
Rep. Maxine WatersD-CA-43 · Jun 12, 2019

Mr. Chair, I have an amendment at the desk. Mr. Chair, my amendment simply removes $1 million from the Administration for Children and Families programs account, but it replaces it back in the very…

Virginia Foxx
Rep. Virginia FoxxR-NC-5 · Jun 12, 2019

Mr. Chairman, I rise in opposition. Mr. Chairman, Job Corps is meant to be an outlet to help disadvantaged youth gain the skills necessary to achieve a good education and the skills needed for the…

James P. McGovern
Rep. James P. McGovernD-MA-2 · Jun 12, 2019

Mr. Chairman, I have an amendment at the desk. Mr. Chairman, I yield myself 2 minutes. Mr. Chairman, I rise in support of my amendment to H.R. 2740, which will ensure that seniors have access to…

Robert C. "Bobby" Scott
Rep. Robert C. "Bobby" ScottD-VA-3 · Jun 12, 2019

Mr. Chair, I have an amendment at the desk made available by the rule. Mr. Chair, I rise in support of this amendment to protect construction and shipyard workers from exposure to beryllium, an…

Donna E. Shalala
Rep. Donna E. ShalalaD-FL-27 · Jun 12, 2019

Mr. Chair, I have an amendment at the desk. Mr. Chair, last week The Washington Post reported that the administration is canceling English classes, recreational programs, and legal aid for…

Peter A. DeFazio
Rep. Peter A. DeFazioD-OR-4 · Jun 12, 2019

Mr. Chairman, I have an amendment at the desk. Mr. Chairman, I yield myself such time as I may consume. Mr. Chairman, I rise in strong support of this amendment to preserve the Job Corps Civilian…

Bill Text

Latest available legislative text

Reading Mode
Latest
Introduced in HouseIssued June 3, 2019

I

116th CONGRESS

1st Session

H. R. 3073

IN THE HOUSE OF REPRESENTATIVES

June 3, 2019

Mr. Smith of New Jersey (for himself and Mr. Peterson) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To provide assistance to combat the escalating burden of Lyme disease and other tick and vector-borne diseases and disorders.

1.

Short title

This Act may be cited as the Ticks: Identify, Control, and Knockout Act or the TICK Act.

2.

Office of Oversight and Coordination for Vector-Borne Disease

(a)

Establishment

The Secretary of Health and Human Services (referred to in this Act as the Secretary) shall establish in the Office of the Secretary an Office of Oversight and Coordination for Vector-Borne Diseases (referred to in this Act as the Office), to be headed by a director to be appointed by the Secretary.

(b)

Duties of the Office

(1)

In general

The Director of the Office shall—

(A)

oversee the creation and maintenance of a national strategy to address Lyme disease, and other tick and vector-borne diseases as provided for in paragraph (2); and

(B)

oversee and coordinate Lyme disease and other tick and vector-borne disease and disorder programs and activities across the agencies and offices of the Department of Health and Human Services and other Federal agencies outside of the Department of Health and Human Services, as appropriate.

(2)

National strategy

(A)

In general

The Director of the Office shall provide for the conduct of an annual assessment of the progress of the United States in preparing for the escalating burden of Lyme disease and other tick and vector-borne diseases and disorders, including an assessment of all Federally funded programs and activities related to surveillance, diagnosis, treatment, education, or prevention, as well as implementation steps, and recommendations for priority actions, with appropriate benchmarks to measure progress, based on the assessment.

(B)

Non-Federal perspectives

In developing the strategy under subparagraph (A), and maintaining it, the Director shall consult with non-Federal individuals with appropriate expertise, which may include—

(i)

epidemiologists with experience in surveillance, treatment, education, or prevention of vector-borne diseases;

(ii)

representatives of national patient advocacy and research organizations that focus on vector-borne diseases, and those that focus specifically on tick-borne disease and have demonstrated experience in research, data collection, or patient access to care;

(iii)

health information technology experts or other information management specialists;

(iv)

clinicians, entomologists, vector-management professionals, integrated pest management professionals, public health professionals, and others with expertise in vector-borne disease, including Lyme disease or other tick-borne diseases or disorders; and

(v)

research scientists with experience conducting translational research or utilizing surveillance systems for scientific research purposes.

(c)

Objective of the Office

In carrying out subsection (b), the Director of the Office shall facilitate and work to ensure the accomplishment of the following activities:

(1)

Expansion and enhancement of epidemiological research and basic, translational, and clinical biological and biomedical research.

(2)

Expansion and improvement of tick surveillance, linking tick surveillance to surveillance of Lyme disease, and reporting of Lyme disease and other tick- and vector-borne diseases, including coinfections with agents of more than one tick or vector-borne diseases.

(3)

Development of effective diagnostic tests to accurately and timely diagnose Lyme disease and other tick- and vector-borne diseases, including direct detention tests.

(4)

Development of treatments to cure or improve the lives of those who are infected with Lyme disease or other tick-and vector-borne diseases or who suffer from a tick-induced disorder (such as tick PIM programs).

(5)

Address the quality of patient care, treatment affordability, and public awareness of Lyme disease and other tick or vector-borne diseases.

(6)

Design and conduct clinical trials of sufficient size and duration to support clinical recommendations.

(7)

Systematic documentation of the experiences of health care professionals in diagnosing and treating tick- and vector-borne disease, including diagnostic and treatment outcomes.

(8)

Development and maintenance of one or more registries of patients and their experiences relating to exposure to, diagnosis for, and treatment of tick- and vector-borne disease, including outcomes, such that the confidentiality and safety of patient data is protected.

(9)

Access to data and enable emerging technologies to improve patient care, sharing data with researchers and care providers.

(10)

Coordination with other Federal departments to address tick- and other vector-borne diseases including the Department of Defense, the Department of Agriculture, the Environmental Protection Agency, the Department of Interior, and the Department of Homeland Security.

(11)

Coordination with the Tick-Borne Disease Working Group established under section 2062 of the 21st Century Cures Act (42 U.S.C. 284s) to develop and implement recommendations.

(12)

Coordination with international bodies to integrate and inform the fight against Lyme disease, and other tick- and vector-borne diseases globally.

3.

Regional Centers of Excellence in Tick and Vector-Borne Diseases

(a)

In general

The Secretary, in coordination with the Director of the Centers for Disease Control and Prevention and the heads of other agencies as appropriate, shall award grants, contracts, or cooperative agreements to eligible entities (such as institutions of higher education, State, tribal, and local health departments, associations, or other appropriate entities) for the establishment or support of Regional Centers of Excellence in Tick and Vector-Borne Diseases. Such Regional Centers shall be designed to address Lyme disease and other tick and vector-borne diseases by—

(1)

building collaboration between academia and public health agencies for surveillance, prevention and response to Lyme disease and other tick and vector-borne diseases;

(2)

providing training for public health entomologists to deal with Lyme disease and other tick and vector-borne diseases; and

(3)

conducting applied research to develop and validate prevention and control tools and methods, and to anticipate and respond to outbreaks of Lyme disease and other tick and vector-borne diseases.

(b)

Eligibility

To be eligible to receive a grant, contract, or cooperative agreement under this section, an entity shall prepare and submit to the Secretary an application at such time, in such manner, and containing such agreements and information as the Secretary may require, including a description of how the entity will—

(1)

coordinate, as applicable, with existing Federal, State, and tribal programs related to Lyme disease and other vector-borne diseases;

(2)

examine, evaluate, and promote evidence-based interventions for individuals with Lyme disease and other tick- and vector-borne diseases, including those in rural and underserved populations, and those who provide care for such individuals; and

(3)

prioritize activities relating to—

(A)

expanding efforts, as appropriate, to implement evidence-based practices to address Lyme disease and other tick- and vector-borne diseases, including through the training of State, local, and tribal public health officials and other health professionals on such practices;

(B)

supporting surveillance of vectors, and early detection and diagnosis of Lyme and other tick- and vector-borne diseases, including improving the quality and reliability of diagnostic tools at all stages of disease progression, and developing a Lyme disease test capable of distinguishing between past and active infections;

(C)

improving the safety and efficacy of any new, renewed, or modified human vaccine for Lyme disease, other tick- and vector-borne diseases, or a combination of such diseases;

(D)

developing a standardized screening protocol for Lyme disease and other tick- and vector-borne diseases;

(E)

enhancing studies and activities on tick biology, disease ecology, and surveillance, and tick management; and

(F)

supporting other relevant activities identified by the Secretary or the Director of the Centers for Disease Control and Prevention, as appropriate.

(c)

Considerations

In awarding grants, contracts, and cooperative agreements under this section, the Secretary shall consider, among other factors, whether the entity—

(1)

provides services to rural areas or other underserved populations;

(2)

is able to build on an existing infrastructure of services and public health research;

(3)

is located in an area with a high prevalence, or in any area predicted to have a high prevalence, of Lyme disease or other tick- and vector-borne diseases; and

(4)

has experience with conducting research related to Lyme disease and other tick- and vector-borne diseases.

(d)

Authorization of appropriations

For the purpose of carrying out this section, there are authorized to be appropriated $10,000,000 for each of fiscal years from 2021 through 2026. Amounts appropriated shall be allocated under this section to diseases in a manner that proportionately matches the disease burden of those diseases in the United States, which shall be reassessed and adjusted annually.

4.

Cooperative agreements with the Centers for Disease Control and Prevention

(a)

In general

The Secretary, in coordination with the Director of the Centers for Disease Control and Prevention and the heads of other agencies, as appropriate, shall enter into cooperative agreements between the Centers for Disease Control and Prevention and health departments of States, political subdivisions of States, and Indian tribes and tribal organizations, to address Lyme Disease and other tick- and vector-borne diseases, and to support the development and implementation of evidence-based research, interventions, and treatment with respect to—

(1)

educating and informing the public, based on evidence-based public health research and data, about Lyme Disease and other vector-borne diseases;

(2)

supporting early detection and diagnosis;

(3)

supporting prevention;

(4)

improving treatment;

(5)

supporting care planning and management for individuals with Lyme disease and other tick- and vector-borne diseases; and

(6)

supporting other relevant activities identified by the Secretary or the Director of the Centers for Disease Control and Prevention, as appropriate.

(b)

Eligibility

To be eligible to enter into a cooperative agreement under this section, an entity described in subsection (a) shall prepare and submit to the Secretary an application at such time, in such manner, and containing such information as the Secretary may require, including a plan that describes—

(1)

how the applicant proposes to develop or expand programs to educate individuals through partnership engagement, workforce development, guidance and support for programmatic efforts, and evaluation with respect to Lyme disease and other tick- or vector-borne diseases, and how the applicant proposes to support other relevant activities identified by the Secretary or the Director of the Centers for Disease Control and Prevention, as appropriate;

(2)

the manner in which the applicant will coordinate with Federal, tribal, and State programs related to Lyme Disease and other vector-borne diseases, and appropriate State, tribal, and local agencies, as well as other relevant public and private organizations or agencies; and

(3)

the manner in which the applicant will evaluate the effectiveness of any program carried out under the cooperative agreement.

(c)

Authorization of appropriations

-For the purpose of carrying out this section, there are authorized to be appropriated $20,000,000 for each of fiscal years 2021 through 2026. Amounts appropriated shall be allocated under this section to diseases in a manner that proportionately matches the disease burden of those diseases in the United States, which shall be reassessed and adjusted annually.